Bernard Jozef Coulie
President, CEO & DirectorDr. Bernard Jozef Coulie M.D., Ph.D., M.B.A. serves as an Independent Director at Redx Pharma Limited since August 27, 2026. He is Independent Director of Biogazelle NV. Dr. Coulie is Independent Director of Septerna, Inc. from December 2023. He served as Independent Director at SQZ Biotechnologies Company since July 2021 until March 2024 and served as its Independent Chairman since November 2022 until March 2024. He serves as President and Chief Executive Officer of Pliant Therapeutics Inc. and serves as its Director since February 2016. He serves as the Independent Chairman of the Board at Calypso Biotech SA. He served as the Chief Executive Officer and Chief Medical Officer at ActoGeniX NV. from September 2006 until February 2015. He served as a Vice President of Research & Development. He served as a Therapeutic Area Leader at Johnson & Johnson. He served as Director of ActoGeniX. He was a Member of the Board of Directors of Sopartec SA. He joined Pliant from ActoGeniX (acquired by Intrexon Corporation in February 2015), where he was Chief Executive Officer, Chief Medical Officer and Co-Founder. In these positions, he played an integral role in advancing the company’s unique technology platform for oral delivery of biologics from early discovery stage through Phase 2 studies. Prior to ActoGeniX, he held various positions with increasing responsibilities in drug discovery and clinical development at Johnson & Johnson Pharmaceutical Research and Development Europe. At Johnson & Johnson, he served as Therapeutic Area Leader Internal Medicine, managing a portfolio of products in GI, metabolic diseases and inflammation/immunology, ranging from early drug discovery through Phase 2 studies. He served as a Director of ActoGeniX from April 2010 until February 2015, Biogazelle N. V. from July 2015 until November 2018 and Myoscience from June 2016 until March 2019. Earlier in his career, he was a Staff Physician in the Department of Gastroenterology and Hepatology at Mayo Clinic (Rochester, MN), Assistant Professor in Medicine at Mayo Medical School and a Mayo Foundation scholar. Dr. Coulie is currently serving as a director and Chairman of Dualyx NV. Dr. Coulie is currently serving as a director and Chairman of Flindr Therapeutics B.V., a privately held precision oncology company based in the Netherlands; as a director and Chairman of RAGE Biotech Pty Ltd, a privately held chronic inflammatory disease company based in Australia. He also serves as a director at the Charcot-Marie-Tooth Association, a patient advocacy organization dedicated to the development of new drugs to treat Charcot-Marie-Tooth disease. He holds an M. D. and Ph. D. from the University of Leuven, Belgium. He is a board-certified internist and he holds an MBA from the Vlerick Leuven Gent Management School (Vlerick Business School), Leuven, Belgium.
公司职务
- 公司名称Pliant Therapeutics, Inc.股票代码PLRX职务President, CEO & Director共事同僚
- HHHoyoung HuhIndependent Chairman & Lead Director
- KLKeith Lamont CummingsChief Financial Officer
- MKMinnie KuoChief Operating Officer
- RDRik DerynckScientific Founder & Member of Scientific Advisory Board
- DSDean SheppardScientific Founder & Member of Scientific Advisory Board
- HCHal ChapmanScientific Founder & Member of Scientific Advisory Board
